Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Must have received: androgen deprivation therapy (LHRH agonist, LHRH antagonist, orchiectomy) — neoadjuvant and/or adjuvant, or in conjunction with salvage radiation

Patients may have received neoadjuvant and/or adjuvant LHRH therapy during definitive treatment or salvage radiation; if so at least 12 months must have elapsed from the last LHRH injection and baseline testosterone must be > 150 ng/dL

Must have received: androgen deprivation therapy (LHRH agonist, LHRH antagonist, orchiectomy) — neoadjuvant and/or adjuvant

Patients may have received prior androgen deprivation therapy (ADT) -neoadjuvant and/or adjuvant, or in conjunction with salvage radiation - but it must not have lasted for more than 36 months. Single or combination therapy allowed. At least 6 months must have elapsed since completion of androgen deprivation therapy in the neoadjuvant and/or adjuvant setting, and serum testosterone must be > 150 ng/mL within 28 days prior to registration.

Cannot have received: ketoconazole, aminoglutethimide, or enzalutamide (ketoconazole, aminoglutethimide, enzalutamide)

Patients must not have received prior and/or must not have any plans for receiving concomitant therapy with ketoconazole, aminoglutethimide, or enzalutamide (MDV3100).

Cannot have received: cytotoxic chemotherapy

Exception: Prior cytotoxic chemotherapy with curative intent in the neoadjuvant or adjuvant setting may be allowed at the discretion of the principal investigator. At least 2 years must have elapsed since completion of cytotoxic chemotherapy in the neoadjuvant and/or adjuvant setting

Patients must not have received any prior cytotoxic chemotherapy for metastatic prostate cancer

Cannot have received: abiraterone, apalutamide, or other intensification agent (abiraterone, apalutamide)

Subjects may not already be taking abiraterone, enzalutamide, apalutamide or other intensification agent during this time - bicalutamide is permitted

Cannot have received: investigational agents, concurrent biological, chemotherapy, or radiation therapy

Exception: Previous experimental therapy must have been completed at least 28 days prior to registration

Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy. Previous experimental therapy must have been completed at least 28 days prior to registration